Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mazisotine DDI with Metformin
NCT05615467Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ly3556050 in diabetic polyneuropathy (DPN), osteoarthritis (OA) and chronic low back pain (CLBP), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve of Metformin and Maximum Observed Drug Concentration of Metformin. Started Nov 2022; status: completed.
02
Drugs
ly3556050
03
Conditions
diabetic polyneuropathy (DPN)osteoarthritis (OA)chronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT05615467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05615467.